Diagnostic triage for sarcoma: an effective model for reducing referrals to the sarcoma multidisciplinary team

Shah, Amit; Botchu, Rajesh; Ashford, Robert U.; Rennie, Winston J.

doi:10.1259/bjr.20150037

Cited by 12 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research into novel models for diagnosis and referral practices further supports the need for improvement in this area. 52 Furthermore, the panel highlighted significant unmet needs with regard to currently available treatments. Experts strongly agreed with the need for new and innovative 1L DDLPS treatments, which is reflected in the limited clinical trials and drug approvals.…”

Section: Discussionmentioning

confidence: 99%

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report

Schöffski,

Jones,

Agulnik

et al. 2024

ESMO Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report

Schöffski,

Jones,

Agulnik

et al. 2024

ESMO Open

View full text Add to dashboard Cite

“…2012, Shah et al. 2015). We did not find a high proportion of repeated scans, as reported from other countries (Ashwood et al.…”

Section: Discussionmentioning

confidence: 99%

Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma

et al. 2017

View full text Add to dashboard Cite

Background and purposeThe use of point-of-care or local investigations before referral to specialist sarcoma centers as part of a fast-track diagnostic pathway varies, and may affect the time to diagnosis. We wanted to investigate differences in time intervals and proportion of malignancy in patients who were referred after initial diagnostic investigations were performed locally and in patients who were referred without these investigations.Patients and methodsWe included 545 consecutive patients who were referred to Aarhus Sarcoma Center for suspected musculoskeletal sarcoma. Data on time intervals and investigations performed were collected from questionnaires and patient records. Patients who were referred from outside Aarhus uptake area after initial MRI/CT or histology performed locally were compared with patients who were referred from Aarhus uptake area without these investigations.ResultsThe median total interval from first symptom to diagnosis was 166 days for outside patients referred with MRI/CT or histology, which was 91 (95% CI: 76–106) days longer than for local patients who were referred without MRI/CT or histology. Comparing the same groups, the median diagnostic interval was 41 (95% CI: 30–51) days longer for outside patients including both primary care and hospital intervals. Both the proportion of malignancies (38% vs. 14%) and the proportion of sarcomas (24% vs. 7%) were higher in the outside group referred with MRI/CT or histology than in the local group without MRI/CT or histology.InterpretationPre-referral investigations at a local hospital increased the diagnostic interval by at least 1 month for 50% of the patients, and the proportion of malignancy was more than doubled—to almost 40%. If investigations are to be performed before referral to a sarcoma center, they should be part of the fast-track pathway in order to ensure timely diagnosis.

show abstract

“…SDTMs consist of a sarcoma MSK radiologist, a sarcoma surgeon, specialist sarcoma pathologist and a multidisciplinary team (MDT) coordinator who are tasked with reviewing new referrals with prior imaging at locality level, before referring appropriate cases to the main sSMDT. Nearly 80% of new referrals are managed locally by the SDTM, suggesting that the diagnostic triage was effective in reducing the rate of inappropriate or benign referrals to the sSMDT (Shah, Botchu, Ashford, & Rennie, 2015).…”

Section: Referral Pathwaysmentioning

confidence: 99%

Sarcomas: Bone and soft tissue tumours

Toh

Hassan

Raurell

2017

InnovAiT: Education and inspiration for general practice

View full text Add to dashboard Cite

S arcoma describes a group of malignant, connective tissue tumours of mesenchymal origin; i.e. arising from fat, muscle, bone, blood vessels and nerves. They are rare and typically account for approximately 1.2% of all cancers in the UK. The incidence of sarcomas is highest in young and old people. Early diagnosis followed by prompt and appropriate treatment is vital to reduce the mortality from sarcomas. This article focuses on increasing primary care awareness of the key clinical features of sarcoma and providing an update on relevant guidelines. Management of sarcoma in tertiary centres is also discussed. The GP curriculum and sarcomas Clinical module 3 20: Care of people with musculoskeletal problems states that GPs should be able to:. Assess the importance of presenting features. Identify 'red flags' that relate to cancer. Understand the challenge of some musculoskeletal conditions that may be better and more confidently managed by other healthcare personnel and refer those conditions which may benefit from early referral. Describe the key national guidelines that influence healthcare provision for musculoskeletal conditions ! The Author(s) 2017. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav

show abstract

Diagnostic triage for sarcoma: an effective model for reducing referrals to the sarcoma multidisciplinary team

Abstract: Cite this article as: Shah A, Botchu R, Ashford RU, Rennie WJ. Diagnostic triage for sarcoma: an effective model for reducing referrals to the sarcoma multidisciplinary team. Br J Radiol 2015;88:20150037.

Cited by 12 publications

References 12 publications

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report

Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma

Sarcomas: Bone and soft tissue tumours

Contact Info

Product

Resources

About